These microbial metabolites demonstrate immunomodulatory capacity to suppress synovial IL-17A secretion while enhancing Treg differentiation, highlighting novel therapeutic avenues for RA management [67,95,96]. The gene discussed is IL17A; the disease is rheumatoid arthritis.